Novavax (NVAX) Non-Current Deferred Tax Liability (2018 - 2019)
Novavax's (NVAX) quarterly Non-Current Deferred Tax Liability came in at $2.5 million in Q4 2019, up 68.36% year-on-year from $1.5 million in Q4 2018, and up 68.36% quarter-over-quarter from $1.5 million in Q4 2018.
Novavax (NVAX) Non-Current Deferred Tax Liability (2018 - 2019) Analysis & Trends
Novavax's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $2.5 million for Q4 2019.
- On a quarterly basis, Non-Current Deferred Tax Liability rose 68.36% year-over-year to $2.5 million in Q4 2019; TTM through Dec 2019 was $2.5 million, a 68.36% increase from a year earlier, with the FY2019 full-year figure at $2.5 million, up 68.36% from the prior year.
- Non-Current Deferred Tax Liability improved to $2.5 million in Q4 2019 per NVAX's latest filing, from $1.5 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $2.5 million in Q4 2019 and bottomed at $1.5 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 2.51 Mn |
| Dec 31, 2019 | 2.51 Mn |
| Dec 31, 2018 | 1.49 Mn |
| Dec 31, 2018 | 1.49 Mn |